Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers

2004 ◽  
Vol 44 (5) ◽  
pp. 447-456 ◽  
Author(s):  
Joseph D. Ma ◽  
Anne N. Nafziger ◽  
Joseph S. Bertino
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphisms ◽  
Extensive Metabolizers ◽  
Pharmacokinetic Variability ◽  
Cytochrome P450 Enzymes

Five genetic polymorphisms of cytochrome P450 enzymes in the Czech non-Roma and Czech Roma population samples

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Lucie Dlouhá ◽  
Věra Adámková ◽  
Lenka Šedová ◽  
Věra Olišarová ◽  
Jaroslav A. Hubáček ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphisms ◽  
Metabolic Pathways ◽  
Cytochromes P450 ◽  
Taqman Assay ◽  
Cytochrome P450 Enzymes ◽  
Roma Population ◽  
Czech Population ◽  
Genotype Frequencies ◽  
Pcr Rflp

AbstractObjectivesCytochromes P450 play a role in human drugs metabolic pathways and their genes are among the most variable in humans. The aim of this study was to analyze genotype frequencies of five common polymorphisms of cytochromes P450 in Roma/Gypsy and Czech (non-Roma) population samples with Czech origin.MethodsRoma/Gypsy (n=302) and Czech subjects (n=298) were genotyped for CYP1A2 (rs762551), CYP2A6 (rs4105144), CYP2B6 (rs3745274) and CYP2D6 (rs3892097; rs1065852) polymorphisms using PCR-RFLP or Taqman assay.ResultsWe found significant allelic/genotype differences between ethnics in three genes. For rs3745274 polymorphism, there was increased frequency of T allele carriers in Roma in comparison with Czech population (53.1 vs. 43.7%; p=0.02). For rs4105144 (CYP2A6) there was higher frequency of T allele carriers in Roma in comparison with Czech population (68.7 vs. 49.8%; p<0.0001). For rs3892097 (CYP2D6) there was more carriers of the A allele between Roma in comparison with Czech population (39.2 vs. 38.2%; p=0.048). Genotype/allelic frequencies of CYP2D6 (rs1065852) and CYP1A2 (rs762551) variants did not significantly differ between the ethnics.ConclusionsThere were significant differences in allelic/genotype frequencies of some, but not all cytochromes P450 polymorphisms between the Czech Roma/Gypsies and Czech non-Roma subjects.

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

2010 ◽  
Vol 11 (4) ◽  
pp. 537-546 ◽  
Author(s):  
Ming-Hsien Tsai ◽  
Keh-Ming Lin ◽  
Mei-Chun Hsiao ◽  
Winston W Shen ◽  
Mong-Liang Lu ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Treatment Response ◽  
Genetic Polymorphisms ◽  
Cytochrome P450 Enzymes

scholarly journals Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation

2020 ◽  
Vol 11 ◽  
Author(s):  
Ahmet Muderrisoglu ◽  
Elif Babaoglu ◽  
Elif Tugce Korkmaz ◽  
Mert C. Ongun ◽  
Erdem Karabulut ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Cytochrome P450 ◽  
Drug Treatment ◽  
Genetic Polymorphisms ◽  
Genetic Variants ◽  
Smoking Status ◽  
Turkish Population ◽  
Drug Transporter ◽  
Cytochrome P450 Enzymes ◽  
Quit Smoking

ObjectivesTo determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population.Methods130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) (n = 40), bupropion (n = 47), bupropion + NRT (n = 15), and varenicline (n = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed.ResultsCessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline (p = 0.013). The frequency of ABCB1 1236TT-2677TT-3435TT haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; p = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 (p = 0.652, p = 0.328, respectively), or variants of CYP2B6 (p = 0.514, p = 0.779, respectively).ConclusionGenetic variants of the drug transporter ABCB1 and the 1236TT-2677TT-3435TT haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment.

scholarly journals Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China

2010 ◽  
Vol 9 (3) ◽  
pp. 1844-1851 ◽  
Author(s):  
Z.F. Yang ◽  
H.W. Cui ◽  
T. Hasi ◽  
S.Q. Jia ◽  
M.L. Gong ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphisms ◽  
Cytochrome P450 Enzymes

scholarly journals Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis

2022 ◽  
Vol 24 ◽  
Author(s):  
Carmen Wing Han Chan ◽  
Caixia Li ◽  
Eleven Jinnan Xiao ◽  
Minjie Li ◽  
Patrick Gladson McLeywick Phiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cytochrome P450 ◽  
Genetic Polymorphisms ◽  
Assessment Tool ◽  
Disease Free Survival ◽  
Tamoxifen Treatment ◽  
Breast Cancer Patients ◽  
Cytochrome P450 Enzymes ◽  
Free Survival ◽  
Meta Analyses

Abstract Tamoxifen is commonly prescribed for preventing recurrence in patients with breast cancer. However, the responses of the patients on tamoxifen treatment are variable. Cytochrome P450 genetic variants have been reported to have a significant impact on the clinical outcomes of tamoxifen treatment but no tangible conclusion can be made up till now. The present review attempts to provide a comprehensive review on the associative relationship between genetic polymorphisms in cytochrome P450 enzymes and survival in breast cancer patients on adjuvant tamoxifen therapy. The literature search was conducted using five databases, resulting in the inclusion of 58 studies in the review. An appraisal of the reporting quality of the included studies was conducted using the assessment tool from the Effective Public Health Practice Project (EPHPP). Meta-analyses were performed on CYP2D6 studies using Review Manager 5.3 software. For other studies, descriptive analyses were performed. The results of meta-analyses demonstrated that shorter overall survival, disease-free survival and relapse-free survival were found in the patients with decreased metabolisers when compared to normal metabolisers. The findings also showed that varying and conflicting results were reported by the included studies. The possible explanations for the variable results are discussed in this review.

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

2011 ◽  
Vol 7 (9) ◽  
pp. 1101-1115 ◽  
Author(s):  
Stefano Porcelli ◽  
Chiara Fabbri ◽  
Edoardo Spina ◽  
Alessandro Serretti ◽  
Diana De Ronchi
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphisms ◽  
Cytochrome P450 Enzymes
Sign in / Sign up

Export Citation Format

Share Document